![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PHASE I STUDY FOR SLE PROJECT 57-57 CONCLUDED
PHASE I STUDY FOR SLE PROJECT 57-57 CONCLUDED
The first clinical study with Active Biotech's candidate drug 57-57 against SLE (Systemic Lupus Erythematosus) has been successfully concluded. The Phase I study, which comprised a total of 30 healthy volunteers, was performed in cooperation with the Phase I unit at the Karolinska University Hospital in Stockholm.
The results show that 57-57 is very well-tolerated in all of the studied dose levels, both as single and repeated dose, and that it is well suitable to be given as an oral, daily treatment. Preparations for a patient study (Phase I) with 57-57 are ongoing. This study is planned to start before the year's end.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct